Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, SR-441B, New York, NY, 10065, USA.
J Hematol Oncol. 2021 Jan 6;14(1):5. doi: 10.1186/s13045-020-01018-6.
Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many, treatment can be deferred for years. However, some patients will have an accelerated course and may experience transformation into aggressive lymphomas. In this review, we focus on management concepts shared across iNHLs, as well as histology-specific strategies. We address open questions in the field, including the influence of genomics and molecular pathway alterations on treatment decisions. In addition, we review the management of uncommon clinical entities including nodular lymphocyte-predominant Hodgkin lymphoma, hairy cell leukemia, splenic lymphoma and primary lymphoma of extranodal sites. Finally, we include a perspective on novel targeted therapies, antibodies, antibody-drug conjugates, bispecific T cell engagers and chimeric antigen receptor T cell therapy.
成熟 B 细胞肿瘤，以前为惰性非霍奇金淋巴瘤（iNHL），是一组具有相似疾病过程和治疗模式的异质性恶性肿瘤。大多数 iNHL 患者的预后良好，在许多患者中，治疗可以推迟数年。然而，一些患者会出现加速病程，并可能转化为侵袭性淋巴瘤。在这篇综述中，我们重点关注 iNHL 之间共享的管理概念，以及特定组织学的策略。我们讨论了该领域的悬而未决的问题，包括基因组学和分子通路改变对治疗决策的影响。此外，我们还回顾了罕见临床实体的管理，包括结节性淋巴细胞为主型霍奇金淋巴瘤、毛细胞白血病、脾淋巴瘤和结外部位原发性淋巴瘤。最后，我们探讨了新型靶向治疗、抗体、抗体药物偶联物、双特异性 T 细胞衔接器和嵌合抗原受体 T 细胞疗法。
